Sponsors (3)
Creates a new registration pathway allowing qualified practitioners to prescribe methadone for OUD to be dispensed at pharmacies, with e-prescribing, liquid/tablet forms, telemedicine, and state opt‑outs.
The bill broadens and modernizes access to methadone treatment (pharmacy dispensing and telemedicine) to make care more convenient and safer to manage, but it risks uneven state access, constrained provider supply, diversion, added costs, and privacy concerns that must be managed.
People with opioid use disorder (including rural and mobility-limited patients) can access methadone treatment more easily because pharmacies may dispense methadone and providers may prescribe/monitor via telemedicine, reducing travel and other barriers to care.
Permitting pharmacies to dispense methadone without a separate DEA registration lowers administrative burdens for providers and pharmacies and may expand the number of dispensing locations, improving convenience and continuity of care.
Requiring electronic prescribing and documentation supports safer prescribing by reducing transcription errors and enables better tracking of OUD medications for clinicians and regulators.
States can opt out and block practitioner registrations, creating a patchwork of access that could leave patients in some states without pharmacy-based methadone options.
Limiting eligible prescribers to board-certified addiction specialists or those specifically approved by HHS risks constraining the provider supply and slowing rollout, especially in underserved and rural areas.
Expanding pharmacy dispensing increases potential diversion or misuse risks unless monitoring, quantity limits, and enforcement are robustly implemented.
Based on analysis of 3 sections of legislative text.
Official title: To expand access to methadone through alternative care models using pharmacies.
Introduced July 20, 2026 by Donald Norcross · Last progress July 20, 2026
Creates a new federal registration pathway allowing qualified practitioners to prescribe methadone for opioid use disorder (OUD) that can be dispensed through pharmacies for supervised or unsupervised use. It permits telemedicine prescribing, requires electronic prescriptions and liquid or dispersible tablet formulations, and lets states opt out by asking the Attorney General to stop practitioner registrations. Clarifies DEA/HHS roles for practitioner qualification and reporting: the Attorney General registers providers after consulting HHS, may register board‑certified addiction specialists or other HHS‑qualified clinicians, exempts pharmacies from a separate DEA dispenser registration for this pathway, and requires DEA reporting to Congress on registrations, opt‑outs, enforcement actions, and pharmacy ordering. The law takes effect 180 days after enactment.